
    
      We hypothesize that pretreatment with anti-IgE mAb will greatly reduce the side effects and
      allergic reactions that occur during oral desensitization to peanut and will enhance the
      development of oral tolerance in patients with severe peanut allergy.

      We will follow the patients for 5 years following study completion.
    
  